PFAS risk assessment needs a single clinical frame across workplace and community exposure
Perfluoroalkyl substances sit at an awkward intersection of medicine, toxicology, and public health. Akio Koizumi’s editorial in Industrial Health argues that risk assessment cannot stay split between occupational medicine and environmental health if clinicians want a rational response to PFAS exposure. The point is not academic housekeeping. It is about how exposure gets recognized, how patients are followed, and how evidence is translated into decisions when contamination comes from both jobsites and the surrounding environment.
PFAS persist because their chemistry makes them resistant to breakdown. That persistence is exactly why the same compounds can appear in drinking water, soil, industrial settings, and biologic samples from exposed workers and residents. Once a substance behaves this way, the old fence-line model of occupational risk assessment becomes too narrow. Exposure no longer ends at the factory gate, and the health consequences can no longer be assigned neatly to a single setting.
The editorial centers on perfluoroalkyl substances as a shared problem for occupational medicine and environmental health. That framing matters because the dose pattern is often mixed: some individuals encounter PFAS through manufacturing, firefighting, or other workplace contact, while others experience background exposure through contaminated water or local environmental sources. In real life, those streams can overlap. A worker may carry a job-related burden and a community-related burden at the same time, which makes attribution difficult and increases the chance that exposure history is underestimated.
This is where risk assessment becomes clinically consequential. If clinicians look only at occupational contact, they may miss a broader environmental burden. If they look only at environmental contamination, they may miss the worker whose exposure intensity rose for years on the job before any community screening occurred. The editorial pushes toward a model that treats exposure as cumulative and context dependent, rather than as a binary label attached to one setting.
Koizumi’s argument is grounded in a literature trail that includes Japanese environmental measurements, broader contamination concerns, and recent guidance on PFAS exposure, testing, and clinical follow-up. The references cited in the piece point to surface-water contamination in Japan, environmental contamination around the U.S. Air Force base in Okinawa, and international concern about carcinogenicity. Those citations do not create a single clinical endpoint, but they do establish a pattern: PFAS exposure is not hypothetical, and it is not confined to one discipline’s jurisdiction.
The practical consequence is a call for shared language. Occupational medicine brings exposure history, workplace surveillance, and prevention strategies. Environmental health brings community mapping, contamination pathways, and population-level risk appraisal. Separately, each field can describe part of the problem. Together, they can define a more defensible estimate of who has been exposed, how long exposure may have lasted, and which follow-up steps are warranted. Without that integration, risk assessment can drift toward either overinterpretation of isolated measurements or underrecognition of meaningful chronic exposure.
One sentence in the editorial’s premise captures the larger clinical issue plainly: PFAS exposure does not respect institutional boundaries.
That is why a bridge between disciplines is not a slogan but a methodology. Biomonitoring, environmental sampling, workplace history, and downstream clinical surveillance all belong in the same conversation. Otherwise, the patient who needs follow-up may be labeled as a community case when the exposure is occupational, or as a workplace case when the contamination is environmental. Both errors weaken prevention and make the medical record less useful for future decisions.
The inclusion of the 2023 National Academy guidance on PFAS exposure, testing, and clinical follow-up signals an important shift toward standardization. Clinicians need clearer rules for when to test, what to monitor, and how to interpret exposure in the setting of uncertain thresholds. PFAS are especially challenging because the biology of persistence invites long latency, while the exposure history may be fragmented across multiple homes, jobs, and years. Risk assessment in that setting should be built to handle uncertainty, not hide it.
Another plain reality sits underneath the editorial: contaminated water and industrial exposure can produce the same biomarker signals while demanding different prevention strategies. A blood test can identify burden, but it cannot by itself explain source, timing, or future risk. That is where integrated occupational-environmental analysis becomes indispensable. It allows clinicians and regulators to move from a measurement to a preventive response.
The editorial is brief, but its agenda is broad. It calls for industrial health to serve as a meeting point for two fields that have often worked in parallel. For PFAS, parallel work is no longer enough. The scientific, regulatory, and clinical stakes all hinge on whether exposure is understood as a shared problem spanning workplace and environment, or as two separate problems with the same chemical name.
What remains unresolved is how quickly this integrated approach can be standardized in everyday clinical practice, especially where environmental monitoring is incomplete and occupational histories are thin. Until those methods are aligned, PFAS risk assessment will continue to depend on fragmented evidence and uneven follow-up rather than a common framework.